Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab.

MLA

Lambert, Gilles, et al. “Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab.” Journal of the American College of Cardiology (JACC), vol. 64, no. 21, Dec. 2014, pp. 2299–300. EBSCOhost, https://doi.org/10.1016/j.jacc.2014.07.995.

APA

Lambert, G., Chatelais, M., Petrides, F., Passard, M., Thedrez, A., Rye, K.-A., Schwahn, U., Gusarova, V., Blom, D. J., Sasiela, W., & Marais, A. D. (2014). Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab. Journal of the American College of Cardiology (JACC), 64(21), 2299–2300. https://doi.org/10.1016/j.jacc.2014.07.995

Chicago

Lambert, Gilles, Mathias Chatelais, Francine Petrides, Maxime Passard, Aurélie Thedrez, Kerry-Anne Rye, Uwe Schwahn, et al. 2014. “Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab.” Journal of the American College of Cardiology (JACC) 64 (21): 2299–2300. doi:10.1016/j.jacc.2014.07.995.